D. CARRASCO, M.D.; L. PALLARDO, M.D.; M. PRIETO, M.D.; J.L. MOLL, M.D.; J.M. CRUZ, M.D.; J. BERENGUER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Androgenic-anabolic steroids have been implicated in the genesis of primary liver tumours. Benign hepatic adenomas are rare and, to our knowledge, no previous case associated with long-term treatment with a non-17-alpha alkylated derivative has been described. We report hepatic adenomata in a renal transplant patient who had previously received androgenic treatment for 12 years. Careful questioning showed that the patient had never received a 17-alpha alkylated compound.
A 32-year-old man with Alport's syndrome, on chronic hemodialysis since March 1973, received a cadaveric renal allograft in June 1983. Treatment was started in February 1971, with intramuscular nandrolone phenpropionate,
CARRASCO D, PALLARDO L, PRIETO M, MOLL J, CRUZ J, BERENGUER J. Hepatic Adenomata and Androgen Treatment. Ann Intern Med. ;100:316. doi: 10.7326/0003-4819-100-2-316_1
Download citation file:
Published: Ann Intern Med. 1984;100(2):316.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use